Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31740661 | 0.78 | NOS3 (0.36) | ALDH1A1LMNA | |
| SCHEMBL2084408 | 0.78 | NOS3 (0.36) | ALDH1A1LMNA | |
| SCHEMBL506978 | 0.77 | SLC6A3 (0.44) | ALDH1A1LMNA | |
| SCHEMBL31728874 | 0.77 | APLNR (0.40) | ALDH1A1LMNA | |
| SCHEMBL1193499 | 0.77 | SLC6A3 (0.44) | ALDH1A1LMNA | |
| SCHEMBL1307914 | 0.77 | SLC6A3 (0.44) | ALDH1A1LMNA | |
| SCHEMBL31403759 | 0.76 | SORD (0.37) | ALDH1A1LMNA | |
| SCHEMBL20831947 | 0.72 | ADRA2A (0.34) | ALDH1A1LMNA | |
| SCHEMBL18271132 | 0.71 | SLC6A3 (0.46) | ALDH1A1LMNA | |
| SCHEMBL2666783 | 0.70 | SORD (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867225-B1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-9468661-B2 | Pyrrolidine derivatives and their use as complement pathway modulators | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2015-07-09 | — | — | US | disclosed |
| EP-2867225-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014002054-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | C5, C9, TFPI | ALDH1A1 2025/4885LMNA 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.